Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1307"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"Metabolism and Excretion
Ranolazine is metabolized mainly by CYP3A and, to a lesser extent, by CYP2D6. Following a single oral dose of ranolazine solution, approximately 75% of the dose is excreted in urine and 25% in feces. Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces. The pharmacologic activity of the metabolites has not been well characterized."
|
| dc:creator | |
| dc:date |
"09/24/2009 15:47:51"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ranolazine_primary_total_clearance_mechanism_Metabolic_Clearance, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1503 }